Derrick Eichele, MD
Gastroenterology · Omaha, NENPI 1023304607
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $44,925 of the $53,551 with a category attached, or 83.9%. 27 manufacturers reported payments, led by AbbVie at 56.9% of the total. Reporting peaked in 2024 at $24,876 and has fallen 73.5% since, to $6,601 in 2025. Among gastroenterology clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $194.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$30K
- Pfizer$10K
- Phathom Pharmaceuticals, Inc.$9K
- Johnson & Johnson$670
- Aimmune Therapeutics, Inc.$663
- Sanofi$349
- plus $2K from 21 others
Across 8 payments — averaging $10,978 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$65K
- Takeda Pharmaceuticals U.S.A., Inc.$23K
What the payments were for
- Consulting fees$2,3004%
- Speaking & faculty fees$44,92584%
- Travel & lodging$2370%
- Food & beverage$6,01611%
- Education$730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 78 | $30,490 |
| Pfizer | 10 | $10,079 |
| Phathom Pharmaceuticals, Inc. | 17 | $9,124 |
| Johnson & Johnson(2 entities) | 46 | $670 |
| Aimmune Therapeutics, Inc. | 5 | $663 |
| Sanofi | 16 | $349 |
| Madrigal Pharmaceuticals | 19 | $307 |
| Gilead | 12 | $265 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $197 |
| Lilly USA, LLC | 9 | $196 |
| Regeneron Healthcare Solutions, Inc. | 8 | $169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $134 |
| Ipsen Biopharmaceuticals, Inc | 6 | $127 |
| Bristol Myers Squibb | 7 | $117 |
| Intercept Pharmaceuticals, Inc. | 7 | $115 |
| Steris Corporation | 1 | $101 |
| Olympus America Inc. | 1 | $95 |
| Ironwood Pharmaceuticals, Inc | 4 | $86 |
| Janssen Scientific Affairs, LLC | 1 | $66 |
| Ardelyx, Inc. | 3 | $59 |
| Celltrion USA Inc. | 2 | $32 |
| QOL Medical, LLC | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $17 |
| Merck | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $16 |
| Organon | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,551 in reported general payments places this provider in the 95th percentile of 89 gastroenterology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 12 | $128,319 |
| LinzessLinaclotide | 17 | $10,808 |
| Mesalamine | 14 | $4,301 |
| Sucralfate | 48 | $2,680 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 128 | $2,629 |
| Colestipol Hcl | 19 | $2,040 |
| Balsalazide Disodium | 11 | $1,908 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 13 | $878 |
| Pantoprazole Sodium | 85 | $688 |
| Omeprazole | 24 | $534 |
| Dicyclomine Hcl | 25 | $515 |
| Gavilyte-NSodium Chloride/Nahco3/Kcl/Peg | 28 | $441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Linzess | $30,490 | $139,12829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 89 gastroenterology providers in Nebraska.
Other gastroenterology in Omaha
- Benjamin HallOmaha$154K
- Sandeep MukherjeeOmaha$145K
- Rowen ZettermanOmaha$119K
- Joshua EvansOmaha$34K
- Michael SchaferOmaha$30K
- Peter MannonOmaha$30K
- Helen Fasanya-UptagraftOmaha$26K
- Rajani RangrayOmaha$15K
- Grant HutchinsOmaha$15K
- Trevor PearsonOmaha$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.